Holen Sie sich die Stockscreener-App
79.31
0.81%
-0.65
Handel nachbörslich:
79.40
0.09
+0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$79.96
Offen:
$80.155
24-Stunden-Volumen:
11.57M
Relative Volume:
0.75
Marktkapitalisierung:
$199.15B
Einnahmen:
$63.92B
Nettoeinkommen (Verlust:
$17.43B
KGV:
11.54
EPS:
6.87
Netto-Cashflow:
$17.04B
1W Leistung:
-5.21%
1M Leistung:
+0.32%
6M Leistung:
-17.59%
1J Leistung:
-36.94%
1-Tages-Spanne:
$78.95
$80.31
1-Wochen-Bereich:
$78.95
$84.36
52-Wochen-Spanne:
$73.31
$128.73
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Vergleichen Sie MRK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
79.31 | 210.10B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production - Insider Monkey
Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - The Motley Fool
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest
Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey
Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating - Insider Monkey
Merck KGaA gets EU nod for Ezmekly (MRK:NYSE) - Seeking Alpha
Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions - Yahoo Finance
Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - Insider Monkey
Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges - Investing.com
Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges By Investing.com - Investing.com UK
Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha
Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer - Insider Monkey
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention - Yahoo Finance
The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team - Yahoo Finance
Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally - MarketScreener
Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention - MarketScreener
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill - Business Wire
Verona Pharma (VRNA) Opinions on Merck Acquisition News - Quiver Quantitative
Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer - MSN
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects - MSN
Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more - Seeking Alpha
Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition - Yahoo Finance
Success Tricking FDA Shouldn't Protect Merck, Justices Told - Law360
Merck to Acquire Verona Pharma in $10B Bid - USA Herald
Top Analyst Reports for Microsoft, Alibaba & Merck - TradingView
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Yahoo Finance
With Verona deal, Merck wagers on strength of lung drug’s patents - BioPharma Dive
Merck: Jefferies raises TP after Verona acquisition - MarketScreener
Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating - MarketScreener
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? - Nasdaq
Merck Animal Health gets FDA nod for Bravecto Quantum (MRK:NYSE) - Seeking Alpha
Merck Animal Health's Flea-and-Tick Treatment Approved in U.S. - MarketScreener
QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Business Wire
Merck & Co. Remains In The BD Game After Verona Takeout - insights.citeline.com
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration - Insider Monkey
Merck's doravirine/islatravir under FDA review for HIV (MRK:NYSE) - Seeking Alpha
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
Merck to acquire UK drugmaker Verona Pharma for $10bn - World Pharmaceutical Frontiers
Foley Represents Verona Pharma in $10B Acquisition by Merck - Foley & Lardner LLP
Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance
Merck & Co.’s Verona Acquisition Marks A Return To Respiratory - insights.citeline.com
In a $10B deal, Merck buys cardio developer Verona - BioWorld MedTech
Merck spends $10 billion for Verona, gaining access to its COPD medication - Jacksonville Journal-Courier
Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue (NYSE:MRK) - Seeking Alpha
Merck to buy Verona and its lung drug in $10B deal - BioPharma Dive
Merck to Buy Verona Pharma in $10 Billion Deal - The Wall Street Journal
Merck to acquire Verona Pharma for $10 billion - Reuters
Verona Pharma Stock Jumps 20%. It’s Being Bought for $10 Billion by Merck. - Barron's
Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B - Investopedia
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):